Summary
Johnson & Johnson (JNJ) announced the completion of the divestiture of its Ortho Dermatologics division's U.S. assets to subsidiaries of Valeant Pharmaceuticals International, Inc. This transaction, valued at $345 million in cash, includes key prescription brands such as RETIN-A MICRO®, RETIN-A®, GRIFULVIN®, BIAFINE®, ERTACZO®, and RENOVA®. This divestiture represents a strategic move by Johnson & Johnson to streamline its portfolio and focus on core therapeutic areas. Investors should note that the agreement for this sale was initially announced in July 2011, and its completion marks the finalization of this previously disclosed strategic decision. The cash proceeds will likely be utilized by Johnson & Johnson for various corporate purposes, potentially including reinvestment in growth areas, debt reduction, or shareholder returns.
Key Highlights
- 1Completion of the divestiture of Ortho Dermatologics division's U.S. assets.
- 2Sale price of $345 million in aggregate cash.
- 3Buyer is subsidiaries of Valeant Pharmaceuticals International, Inc.
- 4Divested assets include U.S. prescription brands: RETIN-A MICRO®, RETIN-A®, GRIFULVIN®, BIAFINE®, ERTACZO®, and RENOVA®.
- 5The divestiture was previously announced on July 19, 2011.
- 6Transaction was completed by JNJ subsidiary Janssen Pharmaceuticals, Inc.